Vabysmo
(faricimab-svoa)

Vabysmo is FDA-approved for the treatment of:

These conditions are leading causes of vision loss and blindness due to abnormal blood vessel growth and fluid leakage in the retina.

Off-label use of Vabysmo is limited, but may include other retinal vascular conditions, such as:

Use outside approved indications should only be considered by retinal specialists on a case-by-case basis.

Vabysmo is a bispecific monoclonal antibody that targets two key pathways: VEGF-A (vascular endothelial growth factor A) and Angiopoietin-2 (Ang-2). By inhibiting both, it reduces abnormal blood vessel formation and leakage in the retina, improving vision outcomes. It is the first and only FDA-approved treatment with this dual-action mechanism.

USA: Genentech (a member of the Roche Group)
Mexico: Roche México, S.A. de C.V.
Canada: Roche Canada / Hoffmann-La Roche Limited

Vabysmo is available in all three countries, though access and availability may vary depending on national formularies, reimbursement programs, and pharmacy networks. Canada and Mexico offer cost savings while maintaining full regulatory approval via Health Canada and COFEPRIS, respectively.

Canada: ~30–45% savings vs. U.S. retail prices
Mexico: ~25–40% savings vs. U.S. retail prices

(Savings may vary depending on availability, cold chain requirements, regulatory classification, and market fluctuations.)

Vabysmo is available through retina clinics, ophthalmology specialists, and:

This medication is accessed through fully licensed Canadian pharmacies regulated by Health Canada. All pharmacies included in the MedicalMex network undergo a rigorous review and verification process to ensure compliance with national standards, patient safety, and medication authenticity.

You are working directly with MedicalMex Inc., a U.S.-based company that helps eligible patients safely access affordable medications from Canada — with compliance and full-service concierge support at every step.

This medication is also available through certified pharmacies in Mexico regulated by COFEPRIS (Mexico’s national health authority). All partners in the MedicalMex network must pass a rigorous review and certification process before being approved for patient access.

You are working directly with MedicalMex Inc., a U.S.-based company that manages every detail — from medical and travel logistics to prescription compliance — providing secure, affordable access to life-saving medications from Mexico.

Patients should report any sudden vision changes, severe eye pain, or redness immediately to their retina specialist.

For nAMD and DME:
Eylea (aflibercept)
Lucentis (ranibizumab)
Avastin (bevacizumab, off-label)

For DME:
Ozurdex (dexamethasone intravitreal implant)
Iluvien (fluocinolone implant)
Consultation with a retina specialist is required to determine suitability.